Optimal management of glenohumeral osteoarthritis

Chase B Ansok
Stephanie J Muh
Department of Orthopaedic Surgery,
Henry Ford Hospital, Detroit, MI, USA

Abstract: Glenohumeral osteoarthritis (OA) is defined as progressive loss of articular cartilage, resulting in bony erosion, pain, and decreased function. This article provides a gross overview of this disease, along with peer-reviewed research by experts in the field. The pathology, diagnosis, and classification of this condition have been well described. Treatment begins with non-operative measures, including oral and topical anti-inflammatory agents, physical therapy, and intra-articular injections of either a corticosteroid or a viscosupplementation agent. Operative treatment is based on the age and function of the affected patient, and treatment of young individuals with glenohumeral OA remains controversial. Various methods of surgical treatment, ranging from arthroscopy to resurfacing, are being evaluated. The roles of hemiarthroplasty, total shoulder arthroplasty, and reverse shoulder arthroplasty are similarly reviewed with supporting data.

Keywords: glenohumeral, osteoarthritis, hyaluronic acid, hemiarthroplasty, total shoulder arthroplasty

Introduction

Epidemiology

Osteoarthritis (OA) is the commonest joint disease worldwide and affects over 25 million people in the US alone. The disease carries a profound societal, economical, and psychological burden, particularly in light of the nation’s aging population. The glenohumeral joint is the third most common large joint to be affected following the knee and hip. While the true prevalence of glenohumeral OA is difficult to ascertain, population-based studies have demonstrated that 16.1%–20.1% of adults older than 65 years have radiographic evidence of glenohumeral OA. Other well-established risk factors for glenohumeral OA include female sex, Caucasian race, and obesity. Secondary causes of glenohumeral OA include avascular necrosis, infectious or crystalline arthropathy, prior trauma such as dislocation, and prior surgery. With regard to post-traumatic OA, the largest review to date evaluated 570 patients with a history of instability and found that 19.7% had radiographic evidence of glenohumeral OA at a mean follow-up of 12 years. Arthrogenic factors include age at time of dislocation, presence of a rotator cuff tear, and presence of bony defects of either the glenoid or humerus. By contrast, rheumatoid arthritis is characterized by earlier onset of disease, more rapid progression, and more severe osteopenia than primary or post-traumatic OA. It affects the shoulder in more than 90% of patients with greater than 5 years of rheumatoid disease. Glenohumeral OA must be differentiated from rotator cuff arthropathy, which has an identifiable precipitating cause and a distinct treatment algorithm.
Natural history
The rate of progression of primary glenohumeral OA is impossible to predict, with cartilage loss occurring over months to years. It is important to note that cartilage loss, whether visualized radiographically or arthroscopically, does not necessarily correlate with patient symptoms.8 No study to date has evaluated the progression of arthritic changes in the shoulder in either asymptomatic or symptomatic patients. A 15-year cohort study following the progression of radiographic knee OA found an annual rate of disease progression of 2.8%.9 It is unclear if the shoulder demonstrates a similar course. Unfortunately, there are no known interventions that demonstrably reverse or slow the natural history of early OA.

Over time, OA will result in worsening pain and stiffness, yielding functional limitations and decreased quality of life. These limitations are typically most noticeable with overhead activities and in external rotation. Patients often complain of difficulty falling asleep or waking often due to night pain. The impact of these factors on quality of life and psychological health is well described; Cho et al reported rates of depression and anxiety of 15.2% and 19.5% in a cohort of patients with glenohumeral OA.10 Systematic reviews have clearly demonstrated improvements in health-related quality of life following treatment.11

Pathology
There are numerous biomechanical and biochemical processes involved in the development and progression of glenohumeral OA. The progression of degenerative joint disease should be contrasted with the natural process of aging. With age, the collagen content of cartilage is unchanged, and the collagen becomes less hydrated and more permeable.12 In OA, increased activities of collagenase and matrix metalloproteinases are associated with increased water content, disorganization of the collagen framework, and breakdown of protein proteoglycan content.13 The pathology of OA at the molecular level is the subject of intense research focus and remains incompletely understood. Nuclear factor kappa B (NFκB) promotes the expression of inflammatory cytokines such as interleukin-1β and tumor necrosis factor-α, both of which can induce apoptosis of chondrocytes.14 This can occur independently or in conjunction with formation of cytotoxic reactive oxygen species created by mechanical stress.15

The glenohumeral joint is a diarthrodial joint that is highly dependent on surrounding soft tissues for stability.16 Nonetheless, articular congruity is an important factor with regard to joint stability. The hyaline cartilage of the humeral head is thickest at its center, while the glenoid has thicker cartilage at its periphery, most notably at the anteroinferior aspect.17 These differences in cartilage thickness, as well as the glenoid labrum, yield a congruent joint. However, thinner areas are more susceptible to cartilage injury and degeneration, resulting in exposed subchondral bone. In the setting of OA, there is a progressive increase in the subchondral bone plate thickness, a modification in the architecture of subchondral trabecular bone, and formation of osteophytes at the joint margins (Figure 1). In the glenohumeral joint, the posterior glenoid and central aspect of the humeral head are typically the first areas to get affected.18

Joint incongruity results in abnormal loading of articular cartilage, exacerbating the degeneration of chondrocytes. Cartilage defects have severely limited capacity for healing, as articular cartilage is poorly vascularized, and few undifferentiated cell populations are present near the articular surface.19

Figure 1 Advanced osteoarthritis of the humeral head.
In the setting of glenohumeral OA, capsular thickening and contraction may result in a pronounced internal rotation deficit, furthering the eccentric erosion of the posterior glenoid. As described by Neer, the posterior wear is often associated with a posteriorly subluxated humeral head. When compared to healthy subjects, patients with glenohumeral OA have an increased incidence of glenoid retroversion.

**Diagnosis**

In 1974, Neer described primary glenohumeral OA as a limitation in shoulder movement, loss of joint space, the presence of humeral head osteophytes, and the absence of rotator cuff tear. It remains critically important to different OA from rotator cuff arthropathy. Patient history often provides vital clues. Pain from OA is often localized posteriorly and deep within the joint. It is typically associated with night pain, stiffness, and functional limitations. Patients with a history of trauma to the shoulder or systemic inflammatory disease may have earlier onset of disease.

Physical examination should exclude etiologies of pain outside the shoulder and attempt to identify other pathology within the shoulder, such as tendinosis and bursitis. Neck pain, pain radiating down the arm, and pain with provocative maneuvers such as Spurling’s test suggest a cervical source of pain. A thorough neck and neurovascular examination should always be performed. Pain at the greater tuberosity, weakness, or lag signs suggest rotator cuff disease. Impingement and OA are not mutually exclusive diagnoses, but impingement should be identified nonetheless. Active and passive range of motion of the shoulder should be assessed and compared. Maneuvers such as Neer’s impingement sign, cross-body adduction, and the Hawkins-Kennedy sign should be included in a physical exam.

Radiographs are the keystone to diagnosing and staging glenohumeral OA. As already described, joint space narrowing and posterior glenoid wear are common findings. The presence of subchondral sclerosis and osteophytes from the humeral head, often described as a “goat’s beard”, is an anticipated finding as well (Figure 2). Advanced imaging is rarely necessary for diagnosis but can provide useful information for staging, identification of concomitant labral or rotator cuff pathology, and preoperative planning.

**Classification**

The Walch et al classification was proposed in 1999 following a multicenter study of 151 shoulders in 141 patients. This scheme utilized plain radiographs and 2-dimensional computed tomography. The classification includes five wear patterns of the glenoid. Type A1 describes a centered humeral head with minor glenoid erosion, whereas type A2 describes major central glenoid erosion. The goal of this classification is to define glenohumeral pathology and aid surgeons in preoperative planning; it does not provide information regarding functional performance. Type C refers to a dysplastic glenoid with at least 25° of retroversion. Interobserver and intraobserver reliability varied in studies over the following years; values ranged from 0.37 to 0.60 for interobserver reliability and from 0.34 to 0.87 for intraobserver reliability.

In 2016, Bercik et al proposed a modification to this classification system after performing three-dimensional CT scans on 129 shoulders with primary glenohumeral OA (Figure 3). This new system redefines an A2 glenoid, stating that a line drawn from the anterior to posterior rim of the glenoid must transect the humeral head. It also includes a B3 glenoid, which is described as a posteriorly subluxated humeral head with monoconcavity, posterior wear, and at least 15° of retroversion. Lastly, it includes a type D glenoid, described as any level of glenoid anteversion, or anterior humeral head subluxation of greater than 40%. They reported interobserver and intraobserver reliabilities of 0.703 and 0.882, respectively. The most commonly identified types were A2, B2, and B3.

![Figure 2](https://www.dovepress.com/orthopedic-research-reviews-downloadable-from-httpswww.dovepress.com-by-54.70.40.11-on-01-Sep-2018)

**Figure 2** Advanced osteoarthritis with prominent inferior osteophyte.

Notes: (A) Grashey view; (B) axillary view. The arrow points to the prominent interior osteophyte.
2007, the Federal Drug Administration has approved its use has been approved by the European Medicines Agency since. Of note, while use of hyaluronic acid in the shoulder indications. Topical capsaicin, a transient receptor vanilloid-1 receptor antagonist, has been evaluated in treatment of OA studies. Topical formulations of these medications have not been well pain. Other trials have shown improvement with use of non-steroidal anti-inflammatory drugs to treat shoulder pain, 50%–67% of patients can expect improvement in their using placebo found that active forward elevation improved spective trial by Di Giacomo and De Gasperis comparing 30 patients receiving intra-articular hyaluronic acid to 30 receiving placebo found that active forward elevation improved by 18° compared to 7.8°, active external rotation improved by 7.6° compared to 4.5°, and Constant scores improved by 13.4 points compared to 8.2 points; these findings were all statistically significant (p < 0.05).

These injections are not without risks or side effects. Transient suppression of the hypothalamic–pituitary–adrenal axis by average of 21.5% has been demonstrated, persisting for up to 72 hours. In patients with diabetes mellitus, hyperglycemia and increased ophthalmologic pressures have been well documented. The rate of septic arthritis varies greatly in the literature, but has cited from 1 in 3,000 to 1 in 50,000 cases. With regard to hyaluronic acid, less frequent injections with higher molecular weight preparations appear to have a lower rate of septic arthritis, though this finding was demonstrated in knees rather than the glenohumeral joint.

Numerous studies have elucidated the difficulty in accurately administering intra-articular injections to the glenohumeral joint. Sethi et al found that only 26.8% of anteriorly placed injections were successfully placed in the glenohumeral joint, and Hagedus et al demonstrated successful intra-articular injections in 52.4% of their subjects. However, later studies stand in contrast to these findings, with Rutten et al demonstrating success with an ultrasound-guided approach in 94% of their subjects. Most recently, Kraeutler et al described a technique in which a point 1.0–1.5 cm

![Figure 3 Modified Walch classification.](https://www.dovepress.com/)

**Notes:** A1: Centered humeral head with minor erosion; A2: centered humeral head, major central erosion; B1: posterior subluxated head without bony erosion; B2: posterior subluxated head, posterior erosion with biconcavity of the glenoid; B3: monoconavity with retroversion > 15 degrees; C: dysplastic glenoid with at least 25° of retroversion regardless of erosion; D: glenoid anteverision and/or anterior subluxation. Reprinted from Publication J Shoulder Elbow Surg, 25 /10, Bercik MJ, Kruse K 2nd, Yalizis M, Gauci MO, Chaoui J, Walch G, A modification to the Walch classification of the glenoid in primary glenohumeral osteoarthritis using three-dimensional imaging., 1601–1606, Copyright (2016), with permission from Elsevier.

**Treatment**

**Nonoperative treatment**

The first step of management of primary glenohumeral OA is, with very few exceptions, nonoperative treatment. Acetaminophen in dosages of 3–4 grams daily has been demonstrated to be both safe and effective. While no randomized controlled trials have demonstrated a significant benefit of using non-steroidal anti-inflammatory drugs to treat shoulder pain, 50%–67% of patients can expect improvement in their pain. Other trials have shown improvement with use of oral prednisolone. COX-2 inhibitors have not been shown to be more efficacious. As always, the side effect profile of these medications must be taken into consideration. Most notably, patients with a history of gastrointestinal bleeding or renal disease should discuss use with their primary care physicians or specialists. Oral corticosteroid treatment is not recommended by the American College of Rheumatology.

Topical formulations of these medications have not been well studied. Topical capsaicin, a transient receptor vanilloid-1 receptor antagonist, has been evaluated in treatment of OA of the knee and hand and found to be more effective than placebo with few side effects. Its role in management of glenohumeral OA has not been studied.

Intra-articular injections remain one of the most commonly utilized nonoperative treatments for OA. Of particular interest are the roles of corticosteroids (typically methylprednisolone) and hyaluronic acid, for which there are multiple formulations. Of note, while use of hyaluronic acid in the shoulder has been approved by the European Medicines Agency since 2007, the Federal Drug Administration has approved its use only in knees. Merolla et al compared intra-articular methylprednisolone to Hylan G-F 20 and found that though both groups had significant improvement in pain at 1 month; only the hyaluronic acid had sustained pain relief at 6 months. The largest randomized control trials have demonstrated a decrease in short-term pain scores. Blaine et al evaluated 660 patients with glenohumeral OA and found a threefold decrease in pain in a group receiving Hyalgan® (Fidia Pharma USA Inc, Florham Park, NJ, USA) compared to placebo at 26-week follow-up (p = 0.003). A second trial of 300 patients with chronic shoulder pain found a statistically insignificant decrease in pain (p = 0.112) in a group receiving Supartz® (Bioventus LLC, Durham, NC, USA) compared to placebo. However, in a subgroup of patients with glenohumeral OA as the source of shoulder pain, intra-articular hyaluronic acid was found to be superior (p = 0.028). No randomized clinical trials have assessed shoulder function following intra-articular injections, though numerous small prospective trials, such as those by Brander et al, have shown sustained improvement in the simple shoulder test at 6 months (p = 0.001). A prospective trial by Di Giacomo and De Gasperis comparing 30 patients receiving intra-articular hyaluronic acid to 30 receiving placebo found that active forward elevation improved by 18° compared to 7.8°, active external rotation improved by 7.6° compared to 4.5°, and Constant scores improved by 13.4 points compared to 8.2 points; these findings were all statistically significant (p < 0.05).

![Figure 3 Modified Walch classification.](https://www.dovepress.com/)

**Notes:** A1: Centered humeral head with minor erosion; A2: centered humeral head, major central erosion; B1: posterior subluxated head without bony erosion; B2: posterior subluxated head, posterior erosion with biconcavity of the glenoid; B3: monoconavity with retroversion > 15 degrees; C: dysplastic glenoid with at least 25° of retroversion regardless of erosion; D: glenoid anteverision and/or anterior subluxation. Reprinted from Publication J Shoulder Elbow Surg, 25 /10, Bercik MJ, Kruse K 2nd, Yalizis M, Gauci MO, Chaoui J, Walch G, A modification to the Walch classification of the glenoid in primary glenohumeral osteoarthritis using three-dimensional imaging., 1601–1606, Copyright (2016), with permission from Elsevier.
lateral to the coracoid process and at the anterior joint line is identified, and a 21 gauge 1.5 inch needle is passed at a 45° angle relative to the floor.50 With this technique, success was demonstrated in 93.3% of their 75 patients. These studies demonstrate the need for adherence to a replicable anatomic approach or use of ultrasound to effectively insert a needle intra-articularly.

Physical therapy is often incorporated into a multidisciplinary nonoperative treatment plan. There are no agreed upon treatment models with regard to intensity or duration of therapy. A cognitive approach with supervised physical activity has been suggested.51 No studies have evaluated the efficacy of physical therapy as an isolated treatment. As part of a multimodal treatment plan, sustained improvements in pain and function were seen in a 3-year follow-up in a study of 129 patients aged 65 years and older conducted by Guo et al.52 Surgeons must take into the patient's physiologic and psychologic health when creating a treatment plan for OA.

Operative management
Non-arthroplasty techniques
The operative treatment of glenohumeral OA is reserved for patients who have failed the aforementioned conservative treatments. In elderly or low-demand patients, total shoulder arthroplasty (TSA) is a reliable and highly successful procedure. However, concerns regarding implant longevity and decreased activity levels have led surgeons to pursue joint-preserving procedures in younger and more active patients.53,54 Mitchell et al have reported good early outcomes with their technique of comprehensive arthroscopic management.55 This arthroscopic technique, described in detail by Millet et al, involves extensive capsular release, osteoplasty of the humeral head, treatment of identified SLAP lesions or biceps tenosynovitis, and axillary nerve neurolysis when scarring or compression is noted.56 A review of 107 shoulders at a 2-year follow-up demonstrated that while 15.8% of these patients underwent TSA within 2 years, the remainder reported high satisfaction.57 Unfortunately, similar success has not been reported by all groups. In a cohort of 33 patients, Skelley et al found that pain relief and range of motion were not sustained at 1-year follow-up, and 42.4% of their cohort had undergone arthroplasty within 9 months.58

Isolated cartilage lesions in the shoulder are rare, and they are unlikely to be a predominant source of pain. When present, however, they can be treated in a similar fashion to cartilage lesions elsewhere in the body. So-called palliative treatment—lavage or debridement—is reserved for lesions identified incidentally at the time of arthroscopic management of other conditions about the shoulder.59 In general, the size of the lesion dictates treatment. Small, superficial osteochondral defects can be treated with microfracture and debridement.60 Cameron et al reported 88% of patients experiencing significant pain relief over an average of 28 months;61 Gross et al found good or excellent results in 78% of patients at 30 months.62

Resurfacing
While restorative treatments such as autologous cartilage implantation and autograft transfers have been described, these procedures have limited utility in the shoulder and the long-term results are unknown. Focal prosthetic resurfacing has been studied more extensively. The goal of these operations is to provide pain relief and maintain function while allowing for conversion to TSA at a later date. Ideal candidates for these procedures are young people with minimal glenoid wear and intact rotator cuffs.63 Patients with avascular necrosis and maintained peripheral articular congruity are also candidates.64 Levy et al reported on cementless surface replacement arthroplasty with 54 patients under the age of 50 years.65 They found profound increases in Constant scores (mean increase 11.5%–71.8%, p < 0.0001), with a survival rate of 81.6% at a minimum of 10 years. Iagulli et al also had good outcomes in a cohort of 36 patients aged 55 years and younger; mean visual analog score (VAS) decreased from 7.5 to 1.3 (p < 0.0001) and American Shoulder and Elbow Surgeon (ASES) scores improved from 29.8 to 87.7 (p < 0.001).66 Humeral head inlay arthroplasties have also revealed good short-term results, with Wiater and Fabing reporting a 95% rate of good or excellent results at 8 months in a cohort of 62 patients.67 The longest follow-up study, reported by Sweet et al, showed a mean improvement in ASES scores from 24.1 to 78.8 at an average follow-up of 32.7 months.68

The role of biologic resurfacing has remained controversial since its inception in the late 1980s. Initially described with an autogenous fascia lata graft by Burkhead and Hutton,69 biologic resurfacing intends to avoid metal-on-bone contact and minimize glenoid erosion and pain. Other interposition arthroplasties have made use of Achilles tendon allograft and lateral meniscal allograft; no significant differences have been reported between these agents.70 Krishnan et al reported their results using anterior capsule, autogenous fascia lata, and Achilles tendon allograft.71 They noted 50% excellent results overall, with poorer results in patients in whom anterior capsule was used. Wirth reported significant improvement in ASES, VAS, and Simple Shoulder Test scores in patients who underwent lateral meniscal allograft in
18-month follow-up, with 94% of patients stating they would undergo the procedure again. This was supported by Bois et al, who found similar results with meniscal allograft in 30 patients monitored for an average of 3 years.73

Strauss et al identified 41 patients who had undergone biologic resurfacing of the glenoid in conjunction with humeral head arthroplasty and compared them to those without biologic resurfacing and found relatively high failure rates (30%) in both groups.74 Both groups had similar pain and function at 2.5-year follow-up. Conversely, Somerson et al have had promising results with a ream-and-run procedure in which the glenoid is resurfaced without an arthroplasty.75 At a mean follow-up of 3 years, there were 2 revisions in 30 shoulders, and an average increase in Simple Shoulder Test scores from 5 to 10. In this cohort, the procedure was reserved for those with glenoid retroversion and posterior displacement of the humeral head, and the authors caution a steep learning curve.

Hemiarthroplasty and TSA
The modern total shoulder prosthesis was developed by Neer in 1974, and current designs continue to use a cemented all-polyethylene glenoid component.76 Numerous authors have documented the efficacy of anatomic TSA. It is one of the most rapidly growing procedures in the US, with over a fourfold increase in revisions and fivefold increase in primaries from 2001 to 2010.77,78 A 1982 review by Neer et al reported high satisfaction in all but 4 patients from a cohort of 194 shoulders managed with a minimally constrained TSA at a minimum 2-year follow-up.79 In 1984, Cofield reviewed 73 TSAs implanted with the Neer prosthesis at 2- to 6.5-year follow-up. Active abduction improved by 44°, to an average of 120°. In the absence of postoperative complications, the results were predictably good.80 In a follow-up study, Kelly et al reviewed 89 TSAs at a minimum follow-up of 5 years with similar results in pain and function. Prosthetic survival was 93% at 10-year follow-up and 87% after 15 years.81

Once controversial, hemiarthroplasty (use of a stemmed humeral component without a glenoid component) has been shown to be inferior to TSA with regard to both pain and function.82 TSA allows for a better fulcrum for motion, better strength, and decreased pain. At two-year follow-up, significantly improved Constant scores, forward elevation, and pain scores in TSA were reported by Edwards et al in 2003.83 Moreover, revision rates for hemiarthroplasty may exceed 30% within 10 years and often have unsatisfactory results, with Sperling et al reporting 60% unsatisfactory rate compared to only 10% excellent rate.80 The conversion of a failed hemiarthroplasty as a salvage procedure has also been shown to have very low rates of satisfaction. Carroll et al reported a 47% unsatisfactory rate at 5-year follow-up.84 The largest meta-analysis to date, by Radnay et al, pooled nearly 50 years of studies comparing hemiarthroplasty to TSA and identified a total of 1,952 patients.85 The pooled outcomes showed vastly improved pain and range of motion in the TSA and a far lower revision rate (6.5% vs. 10.2%). Indications for stemmed humeral hemiarthroplasty has generally been replaced by reverse TSA, and indications are now limited to those without glenoid bone stock to support a prosthesis.86 Younger patients still benefit from TSA.87 Sowa et al followed a cohort of 21 patients with a mean age of 55 years and an average follow-up of 13 years. Patients maintained high Constant scores and satisfaction, though two patients had undergone revision.88

Repair of the subscapularis is of paramount importance to prevent anterior instability. Terrier et al showed that a deficient subscapularis induces an upward migration of the humeral head, an eccentric contact pattern, and higher stress within the cement.89 Numerous biomechanical studies have assessed repair techniques; no significant differences in strength have been identified between subscapularis tenotomy or subscapularis peel.90,91 While lesser tuberosity osteotomy shows greater biomechanical strength, this has not been shown to have improved clinical outcomes.92 Jandhyala et al reported that both tenotomy and osteotomy groups had similar clinical function,93 consistent with findings by Ahmad et al.94 Subscapularis-sparing approaches have been attempted, though as of yet the complication rate remains unacceptably high.95

Reverse TSA
In patients with severe rotator cuff deficiency, either full-thickness tearing or fatty infiltration, anatomic TSA may not be a viable treatment option. Reports of primary repair of the supraspinatus at time of arthroplasty have had good results with function and pain, though these patients must be carefully selected. Simone et al reported on 33 patients over a 15-year period with a mean follow-up of 4.7 years; VAS decreased from 4.7 to 1.7, although their complication rate was 15%.96 The use of reverse TSA has rapidly increased following the development of the Grammont reverse prosthesis and its medialized center of rotation.97 Rotator cuff arthropathy is a distinct entity that must be differentiated from primary glenohumeral OA. Reverse prostheses have been used in the management of glenohumeral OA, particularly in elderly patients with biconcave glenoids or severe glenoid...
bone loss. In a cohort of 27 patients and mean follow-up of 54 months, Mizuno et al reported a Constant score increase from 31 to 76 points, with only 1 case of glenoid loosening. Figure 4 shows radiographic demonstrations of four distinct glenohumeral prostheses.

Complications
Shoulder arthroplasty has been proven to be a safe and highly effective procedure, with complication rates similar to or lower than that of hip and knee arthroplasty. The major complications of shoulder arthroplasty include periprosthetic fracture, infection, instability, rotator cuff lesions, loosening of the glenoid component, and neurologic injuries. The rate of periprosthetic fractures is between 1.6% and 2.3% and are often associated with cortical thinning due to osteolysis and osteopenia. Infection rates vary across the literature, but have been reported as high as 4%. Prosthetic joint infections of the shoulder are managed much the same as other arthroplasties, often necessitating placement of an antibiotic spacer and two-stage revision. Anterior instability occurs in 0.9%–1.8% of cases, typically due to failure of subscapularis repair. Aseptic glenoid loosening is uncommon and may not require revision if asymptomatic. Removal of a painful loose component and reaming of the glenoid (leaving a hemiarthroplasty) has been described. Complication rate and poor outcomes have been shown to have an inverse relationship with surgeon volume.

Summary
The management of glenohumeral OA begins with a comprehensive evaluation of the patient. Conservative management includes physical therapy, anti-inflammatory medications, and intra-articular injections. Operative treatment is dictated by patient factors, with younger, more active patients benefitting from non-arthroplasty techniques or those with minimal bone resection. Hemiarthroplasty of the humeral head has largely been replaced by modern TSA, with reverse shoulder arthroplasty as an increasingly utilized treatment in cases of glenoid biconcavity or rotator cuff disease. Optimal management of young patients with end-stage disease remains an important topic of for investigation. Surgeons should be aware of the common complications and pitfalls of arthroplasty.

Disclosure
The authors report no conflicts of interest in this work.

References


54. van der Meijden OA, Gaskill TR, Millett PJ. Glenohumeral joint pres-


56. Millett PJ, Horan MF, Pennock AT, Rios D. Comprehensive Arthroscopic Management (CAM) procedure: clinical results of a


58. Skelley NW, Namdari S, Chamberlain AM, Keener JD, Galatz LM, Yamanuchi K. Arthroscopic debridement and capsule release for the


60. Burkhead WJ Jr, Hutton KS. Biologic resurfacing of the glenoid.


1889–1901.

63. Verstraelen FU, Horta LA, Schotanus MGM, Kort NP, Samijo SK, Wirth MA. Humeral head arthroplasty and meniscal allograft resurfac-

64. van der Meijden OA, Gaskill TR, Millett PJ. Glenohumeral joint pres-


66. Millett PJ, Horan MF, Pennock AT, Rios D. Comprehensive Arthroscopic Management (CAM) procedure: clinical results of a


68. Skelley NW, Namdari S, Chamberlain AM, Keener JD, Galatz LM, Yamanuchi K. Arthroscopic debridement and capsule release for the


70. Burkhead WJ Jr, Hutton KS. Biologic resurfacing of the glenoid.


1889–1901.

73. Verstraelen FU, Horta LA, Schotanus MGM, Kort NP, Samijo SK, Wirth MA. Humeral head arthroplasty and meniscal allograft resurfac-

74. Strauss EJ, Verma NN, Salata MJ, et al. The high failure rate of bio-


84. Carroll RM, Izquierdo R, Vazquez M, Blaine TA, Levine WN, Biglani LU. Conversion of painful hemiarthroplasty to total shoulder arthro-

85. Radnay CS, Setter JK, Chambers L, Levine WN, Biglani LU, Ahmad CS. Total shoulder replacement compared with humeral head replace-


88. Sowa B, Bochenek M, Bühlf M, et al. The medium- and long-term outcome of total shoulder arthroplasty for primary glenohumeral osteo-

89. Terrier A, Larrea X, Malfroy Camine V, Violetti DP, Farron A. Import-


91. van den Berghe GR, Nguyen B, Patil S, et al. Biomechanical evalua-

92. Bois AJ, Whitney JJ, Somerson JS, Wirth MA. Humeral head arthro-


